About Exocell

Trusted by the Scientific Community for Over 30 Years

Nephrology assay expertise to advance the understanding and treatment of diabetes

A leader in research on diabetes, endocrinology, and metabolism, Margo Cohen founded Exocell in 1988 to develop diabetes-related diagnostic products, and subsequently established Glycadia to develop therapeutic products. Under her leadership, Exocell quickly became a leader in nephrology diagnostics with 15 patents and over 2000 research citations. Now a part of Ethos Biosciences, Exocell products continue to serve the top academic, biotech, and pharma research teams across the globe. 

Why choose Exocell Assays from Ethos?

From the original Albuwell ELISA and Creatinine Companion Kits, which have become the gold standard assays for microalbuminuria measurement, the analyte list has expanded to include biomarkers for other conditions that frequently co-occur with diabetes. Regardless of the analyte, each kit embodies our commitment to accurate and precise measurement, with reagents and assays designed to maximize quality and ease-of-use while minimizing variability.

Exocell-publications-

Cited in over 2,100 publications!

Exocell-patents

Granted 16 patents!

Why does on Exocell focus on kidney disease research?

Everyone talks about cancer and heart disease but not many people talk about kidney disease despite its status as the 9th leading cause of death in the United States. Over 700 million people worldwide have Chronic Kidney Disease which translates to over $120 billion in Medicare spending in the U.S. alone. One of the highest impact actions we collectively could make is to identify patients with CKD earlier in the disease cycle, especially because anyone with diabetes or hypertension (1/3 of the U.S. population) are at high risk for CKD. Disease progression can be slowed dramatically the earlier a patient understands their risks, begins medication, and/or changes their lifestyle. CKD is only a part of the picture, though. We also face healthcare challenges in Acute Kidney Injury, Polycystic Kidney Disease, Kidney Cancer, End Stage Renal Disease, and Kidney Transplants. Exocell focuses on advancing the worlds understanding of these different kidney diseases and helping to identify and diagnose them. Better diagnostics in the kidney space will lead to more research, better treatments, and better outcomes for renal disease patients. For more information on this topic, please read our blog ” The Cost of Chronic Kidney Disease (CKD) “.